Botulinum toxin online training for doctors interested?
Are you interested in online training for doctors about botulinum toxin A or do you want to refresh your knowledge about botulinum toxin A?
For information material or to register, please click here: www.smart-muscleconcept.de
Botulinum toxin A (BoNT A) is the first-line therapy for focal spasticity.
We would like to introduce you to the diagnosis, management and treatment of spastic patients with botulinum toxin type A (BoNT-A) and introduce you to the SMART muscle concept.
With this simplified treatment concept, you can also carry out the BoNT-A therapy in your practice with reduced complexity and benefit from many advantages, such as optimal planning and an extended range of therapy. The SMART muscle concept - easy for you, easier for your patients.
The smart muscle concept is intended to reduce complexity and thus immediately enable you to treat spasm patients pragmatically and very effectively with BoNT, even without special prior knowledge.
How does the online training work? The training is divided into 3 modules:
I. Basics,
II. Anatomy and
III. organizational
Each module consists of smaller training units of around 10 to 15 minutes in length dr medical carried out by Axel Schramm.
The SMART training was certified by the botulinum toxin working group with a total of 4 credit points. After completing all modules, you can carry out a learning status query and then receive a certificate of successful participation.
For information material or to register, please click here: www.smart-muscleconcept.de
Oral antispasmodics should only be used if everyday spasticity (with impairment of passive and/or active functions) cannot be adequately controlled despite adequate physical and therapeutic measures (strong consensus).
Indications for the use of oral antispasmodics are often not more pronounced focal, multifocal, i.e. severe segmental spasticity in the sense of a pronounced hemispasticity, paraspasticity as a form of segmental spasticity or generalized spasticity in the sense of a tetraspasticity or also shooting nocturnal spasms after a stroke or craniocerebral trauma (strong consensus).
Spasticity usually has a better risk-benefit ratio (see below) for focal drug injection treatment with botulinum toxin A (BoNT A) and should, as far as feasible, be used before oral antispasmodics are used (strong consensus).
Indications for the use of botulinum toxin A
Botulinum toxin A is currently approved for the following indications.
For the symptomatic treatment of focal spasticity:*
- of the upper extremities in adults
- of the ankle in adult patients after stroke or traumatic brain injury
- with dynamic pointed foot position of the lower extremities in ambulatory patients with infantile cerebral palsy aged 2 years and older
For symptomatic treatment in adults:*
- For symptomatic alternative treatment of idiopathic blepharospasm, hemifacial spasm, and coexisting focal dystonia
- For the symptomatic treatment of cervical dystonia (torticollis spasmodicus) with adult onset.
Promotion
of the following service areas by the
Kassenärztliche Vereinigung Bayerns (KVB):
Treatment of dystonia with botulinum toxin
Treatment of dystonia with botulinum toxin: Pediatrics and adolescent medicine: Neuropediatrics
Treatment of spasmodic dysphonia with botulinum toxin
Treatment of spasms and chronic migraine with botulinum toxin
Treatment of spasmodic dysphonia and chronic migraine with botulinum toxin: Pediatrics and Adolescent Medicine: Neuropediatrics
Treatment of excessive sweating with botulinum toxin
* The BoNT-A units are NOT interchangeable with the units of other BoNT-A preparations on the market
Effect profile of BoNT A between injection and reinjection
Schematic representation
Note: For reasons of better legibility, the masculine form is used for personal designations. Corresponding terms generally apply to all genders in terms of equal treatment. The shortened form of language is for editorial reasons only and does not include any rating.